Does Rallies show Form 4 insider transactions for MYGN?

Yes. Rallies tracks MYGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MYGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MYGN. It does not provide personalized investment advice.

MYGN (Myriad Genetics Inc) Stock Analysis - Insider Trades

Myriad Genetics Inc (MYGN) is a publicly traded Healthcare sector company. As of May 21, 2026, MYGN trades at $3.81 with a market cap of $344.74M and a P/E ratio of -0.86. MYGN moved +6.76% today. Year to date, MYGN is -37.95%; over the trailing twelve months it is -14.38%. Its 52-week range spans $3.53 to $27.55. Analyst consensus is neutral with an average price target of $7.20. Rallies surfaces MYGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MYGN stock inside the company?

Recent MYGN insider activity includes Raha Samraat S. bought 40.00K, Phanstiel S. Louise bought 48.00K, Phanstiel S. Louise bought 50.41K, and Phanstiel S. Louise bought 6.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MYGN Key Metrics

Key financial metrics for MYGN
Metric	Value
Price	$3.81
Market Cap	$344.74M
P/E Ratio	-0.86
EPS	$-4.29
Dividend Yield	0.00%
52-Week High	$27.55
52-Week Low	$3.53
Volume	0
Avg Volume	0
Revenue (TTM)	$829.00M
Net Income	$-399.90M
Gross Margin	69.96%

Recent MYGN Insider Trades

Raha Samraat S. bought 40.00K (~$199.84K) on Mar 9, 2026.
Phanstiel S. Louise bought 48.00K (~$223.73K) on Feb 27, 2026.
Phanstiel S. Louise bought 50.41K (~$242.10K) on Feb 26, 2026.
Phanstiel S. Louise bought 6.10K (~$28.89K) on Feb 25, 2026.

Latest MYGN News

Myriad Genetics Promotes 63-Gene MyRisk Cancer Test with Jackie Tohn Partnership — May 15, 2026
Myriad Genetics to Showcase Six AACR Abstracts, Including Two Podium Precise MRD Findings — Apr 16, 2026
Japan Approves Myriad’s MyChoice Test for Prostate Cancer with Lynparza — Apr 14, 2026
Myriad Genetics’ MyChoice CDx Gains Sole FDA Approval for Zejula Ovarian Cancer Test — Mar 17, 2026
Myriad Genetics CEO Buys 40,000 Shares, Shares Jump 6.9% — Mar 10, 2026

MYGN Analyst Consensus

7 analysts cover MYGN: 0 strong buy, 2 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $7.20.

Common questions about MYGN

Who is trading MYGN stock inside the company?: Recent MYGN insider activity includes Raha Samraat S. bought 40.00K, Phanstiel S. Louise bought 48.00K, Phanstiel S. Louise bought 50.41K, and Phanstiel S. Louise bought 6.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MYGN?: Yes. Rallies tracks MYGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MYGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MYGN. It does not provide personalized investment advice.